TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06989567: A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Sponsor: Asklepion Pharmaceuticals, LLC · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 120 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,555,752

Rescue Site Savings

+$1,037,168

Unlock Full NCT06989567 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06989567 Rescue Dossier →